Litmys and Konovo Form Strategic Partnership to Transform Drug Development Intelligence
核心洞察
Litmys (搜索) and Konovo (搜索) announced a partnership integrating commercial readiness analytics with healthcare stakeholder insights to improve R&D investment decisions.
The collaboration combines Litmys (搜索)' RAMPx (搜索) predictive scoring model with Konovo (搜索)'s network of over 2 million healthcare stakeholders across the US, Europe, and Asia.
The partnership aims to help life sciences companies identify development risks earlier, reduce late-stage failures, and strengthen ROI on R&D investments.
Litmys (搜索), a life sciences commercial strategy consulting firm, and Konovo (搜索), a technology-first healthcare intelligence company, have announced a strategic partnership designed to transform how life sciences companies make R&D investment and clinical development decisions. The collaboration integrates commercial readiness analytics with comprehensive healthcare stakeholder insights to reduce clinical development risk.
Partnership Framework
The partnership leverages Litmys (搜索)' proprietary RAMPx (搜索) commercial success predictive scoring model alongside Konovo (搜索)'s network of over 2 million healthcare stakeholders across the US, Europe, and Asia. This combination provides high-quality primary insights and structured qualitative and quantitative assessments to predict new product potential and commercial viability early in clinical development.
"We enable life science companies to focus early development decisions around the endpoints and clinical trial designs that will drive future uptake and demand by physicians, payers, and patients," said Harris Kaplan, Managing Partner at Litmys (搜索). The collaborative process, termed "Demand Driven Development," helps life sciences companies design and invest in clinical trials with greater confidence while avoiding costly late-stage surprises.
Commercial Impact for Life Sciences
The partnership delivers several key benefits to pharmaceutical and medical device companies:
Earlier Risk Mitigation: Access to real-world clinical insights combined with predictive commercial analytics enables companies to identify and address development risks before costly late-stage failures occur, allowing for more strategic allocation of R&D resources and improved portfolio management.
Reduced Time and Cost: Streamlined access to critical stakeholder perspectives alongside advanced analytics helps compress timelines for market assessment and reduces the overall cost and risk associated with bringing products to market.
Stronger ROI on R&D Investments: The combined capabilities help companies strengthen their R&D pipeline returns by investing with greater confidence in assets with the highest probability of commercial success.
Comprehensive Market Intelligence: Investors and CEOs can develop a 360-degree view of development opportunities by connecting fragmented clinical, payer, and patient insights with rigorous commercial readiness analytics.
Technology Integration
Konovo (搜索)'s Intelligent Platform empowers Litmys (搜索) to execute underlying data collection quickly and effectively, allowing more time to focus on generating actionable insights for clients. The platform enables access to the right audiences at the right depth to generate insights that drive confident decisions.
"The life sciences industry has never been under more pressure to validate assets earlier—and with greater precision," said Tal Rosenberg, Chief Executive Officer of Konovo (搜索). "Our collaboration with Litmys (搜索) is a prime example of what Konovo's Intelligent Platform was built to do: enable our partners and clients to connect with the right audiences, at the right depth, to generate insights that drive confident decisions."
Immediate Availability
The partnership became effective immediately upon announcement, with integrated solutions now available to life sciences companies and venture capital firms worldwide. The collaboration aims to provide executives, researchers, and investors with a clearer, earlier understanding of whether an asset can truly succeed commercially after regulatory approval.
Litmys (搜索) specializes in drug and device development risk assessment and commercial readiness analytics, with headquarters in Santa Fe, New Mexico, and an additional office in Minneapolis, Minnesota. Konovo (搜索) operates as a global healthcare company across the Americas, Europe, and Asia, supporting market research agencies, consultancies, and life science brands with deeper, actionable insights through its Intelligent Platform and expert-guided solutions.